Evidence map›Paper›PMID 30656528›Full record

ArticleJournal of neuro-oncology2019

Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.

D Ryan Ormond, B K Kleinschmidt-DeMasters, Daniel Cavalcante, Elizabeth E Smith, Scott D Cramer, M Scott Lucia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Molecular cancer research : MCR · 2021
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

D Ryan OrmondDepartment of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA. david.ormond@ucdenver.edu.ORCID http://orcid.org/0000-0001-7027-2915
B K Kleinschmidt-DeMastersDepartment of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA.
Daniel CavalcanteDepartment of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA.
Elizabeth E SmithDepartment of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.
Scott D CramerDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.
M Scott LuciaDepartment of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.
University of Colorado Denver · US

Funding

CHD1 and MAP3K7 coordinate deletion in aggressive ERG translocation negative prostate cancerR01CA199741 · NCI · UNIVERSITY OF COLORADO DENVER · PI CRAMER, SCOTT D · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA199741
6 · The paper itself

Abstract

backgroundProstatic carcinoma metastatic to dura is commonly encountered at autopsy, but presenting as a dural or, especially parenchymal, brain metastasis during life is far less common. Our group has been interested in two immunohistochemical (IHC) markers previously shown to be downregulated in particularly aggressive primary prostatic carcinomas: CHD1 and MAP3K7. Here we assess protein expression in clinically-relevant CNS metastases. We also assessed how these two markers correlated with the most common genetic alteration in prostate cancer: TMPRSS2 fusion to ERG (40-60% of carcinomas at the primary site), which places ERG expression under the control of the androgen-regulated TMPRSS2 gene, increasing expression.

designDatabase query, 2000-2016, identified 16 metastases to dura, 5 to brain parenchyma.

resultsFour of five intraparenchymal metastases and 15/16 informative dural-based metastases were ERG-negative (90.5% overall). There was reduced expression of CHD1 in 8/21 and reduced MAP3K7 in 17/21 cases; 7/19 (37%) ERG-negative metastases had dual low expression of CHD1/MAP3K7. ERG-positive cases had high expression of one or both markers.

conclusionMetastatic prostatic carcinoma to CNS demonstrates expression patterns consistent with particularly aggressive behavior. Lower ERG expression in dural and intraparenchymal metastases suggests a possibility that ERG-negative tumors with loss of MAP3K7 may become resistant to standard therapies and diffusely metastasize.

Indexed as

AdenocarcinomaBiomarkers, TumorBrain NeoplasmsDNA-Binding ProteinsDNA HelicasesGene Expression Regulation, NeoplasticHumansMaleMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMeningeal NeoplasmsParenchymal TissueProstatic NeoplasmsPTEN PhosphohydrolaseRetrospective StudiesSerine EndopeptidasesBiomarkers, TumorCHD1 protein, humanDNA-Binding ProteinsDNA HelicasesERG protein, humanMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesPTEN PhosphohydrolasePTEN protein, humanSerine EndopeptidasesTMPRSS2 protein, humanTranscriptional Regulator ERGBrain metastasisCHD1Dural metastasisERGMAP3K7Prostate cancer

Identifiers

PMID30656528
PMCPMC6958997
OpenAlexW2908620524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.